Alfasigma S.p.A. Deal History & Licensing Activity
Alfasigma S.p.A. is a life sciences headquartered in Italy. Over the past three years, Alfasigma S.p.A. has been involved in 1 licensing and acquisition transaction, with a primary focus on Small Molecules (2 deals). The company currently has 9 active clinical trials, primarily in Autoimmune.
Deals (12mo)
1
Active Trials
9
Top Modality
Small Molecules
Focus Area
Autoimmune
Alfasigma S.p.A. Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Alfasigma S.p.A. in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| linerixibat | GSK | Small Molecules | Phase 3 | license | Apr 22, 2026 |
Alfasigma S.p.A. Pipeline Focus
Therapeutic areas and modalities where Alfasigma S.p.A. is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Alfasigma S.p.A. Clinical Pipeline
Alfasigma S.p.A. has 9 active clinical trials across 3 development phases.
3
Unknown
1
Phase 2
5
Phase 3
See How Your Asset Matches Alfasigma S.p.A.'s Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Autoimmune assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Alfasigma S.p.A. Licensing & Deal Activity
Alfasigma S.p.A. is a life sciences company based in Italy that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Alfasigma S.p.A. ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Alfasigma S.p.A. include Autoimmune (5 deals and trials), Metabolic (2 deals and trials), and Solid Tumors (1 deal and trial). In terms of modality, Alfasigma S.p.A. has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Alfasigma S.p.A. and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Alfasigma S.p.A.'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.